News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
280,626 Results
Type
Article (14516)
Company Profile (106)
Press Release (265996)
Multimedia
Podcasts (65)
Webinars (13)
Section
Business (89799)
Career Advice (466)
Deals (15779)
Drug Delivery (73)
Drug Development (37296)
Employer Resources (50)
FDA (6514)
Job Trends (6302)
News (153428)
Policy (14378)
Tag
2027 Genetown Elite (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (1)
Academia (454)
Accelerated approval (13)
Adcomms (8)
Allergies (67)
Alliances (24068)
ALS (56)
Alzheimer's disease (485)
Antibody-drug conjugate (ADC) (101)
Approvals (6705)
Artificial intelligence (205)
Autoimmune disease (40)
Automation (12)
Bankruptcy (150)
Best Places to Work (4430)
BIOSECURE Act (9)
Biosimilars (122)
Biotechnology (40)
Bladder cancer (40)
Brain cancer (30)
Breast cancer (181)
Cancer (1357)
Cardiovascular disease (152)
Career advice (419)
Career pathing (13)
CAR-T (50)
CDC (6)
Cell therapy (155)
Cervical cancer (9)
Clinical research (32545)
Collaboration (747)
Compensation (328)
Complete response letters (33)
COVID-19 (791)
CRISPR (44)
C-suite (437)
Cystic fibrosis (59)
Data (1874)
Denatured (18)
Depression (46)
Diabetes (127)
Diagnostics (1473)
Digital health (8)
Diversity (2)
Diversity, equity & inclusion (14)
Drug discovery (114)
Drug pricing (114)
Drug shortages (12)
Duchenne muscular dystrophy (81)
Earnings (33849)
Editorial (20)
Employer branding (4)
Employer resources (45)
Events (39586)
Executive appointments (532)
FDA (7637)
Fibrodysplasia Ossificans Progressiva (3)
Friedreich's ataxia (2)
Frontotemporal dementia (1)
Funding (442)
Gene editing (72)
Generative AI (18)
Gene therapy (171)
GLP-1 (442)
Government (1419)
Grass and pollen (4)
Guidances (168)
Healthcare (3763)
HIV (11)
Huntington's disease (9)
IgA nephropathy (37)
Immunology and inflammation (71)
Immuno-oncology (14)
Indications (54)
Infectious disease (855)
Inflammatory bowel disease (73)
Inflation Reduction Act (7)
Influenza (24)
Intellectual property (117)
Interviews (61)
IPO (5999)
IRA (33)
Job creations (2069)
Job search strategy (375)
JPM (28)
Kidney cancer (9)
Labor market (28)
Layoffs (205)
Leadership (8)
Legal (3537)
Liver cancer (22)
Longevity (8)
Lung cancer (189)
Lymphoma (124)
Machine learning (13)
Management (17)
Manufacturing (420)
MASH (67)
Medical device (1458)
Medtech (1466)
Mergers & acquisitions (10209)
Metabolic disorders (435)
Multiple sclerosis (47)
NASH (14)
Neurodegenerative disease (82)
Neuropsychiatric disorders (38)
Neuroscience (900)
Neurotech (1)
NextGen: Class of 2026 (1613)
Non-profit (601)
Now hiring (17)
Obesity (227)
Opinion (141)
Ovarian cancer (39)
Pain (115)
Pancreatic cancer (52)
Parkinson's disease (81)
Partnered (11)
Patents (225)
Patient recruitment (124)
Peanut (12)
People (30074)
Pharmaceutical (63)
Pharmacy benefit managers (18)
Phase 1 (8491)
Phase 2 (13758)
Phase 3 (12357)
Pipeline (1943)
Policy (135)
Postmarket research (1427)
Preclinical (3406)
Press Release (25)
Prostate cancer (87)
Psychedelics (16)
Radiopharmaceuticals (139)
Rare diseases (355)
Real estate (2721)
Recruiting (18)
Regulatory (11138)
Reports (15)
Research institute (588)
Resumes & cover letters (55)
Rett syndrome (5)
RNA editing (6)
RSV (20)
Schizophrenia (69)
Series A (85)
Series B (48)
Service/supplier (3)
Sickle cell disease (46)
Special edition (10)
Spinal muscular atrophy (81)
Sponsored (9)
Startups (1685)
State (2)
Stomach cancer (5)
Supply chain (50)
Tariffs (68)
The Weekly (45)
Vaccines (234)
Venture capital (32)
Weight loss (140)
Women's health (27)
Worklife (4)
Date
Today (3)
Last 7 days (176)
Last 30 days (680)
Last 365 days (10637)
2026 (980)
2025 (10932)
2024 (12718)
2023 (14535)
2022 (20467)
2021 (20944)
2020 (19645)
2019 (15254)
2018 (11938)
2017 (14222)
2016 (13421)
2015 (15858)
2014 (12716)
2013 (10822)
2012 (11682)
2011 (12164)
2010 (11098)
Location
Africa (320)
Alabama (19)
Alaska (1)
Arizona (78)
Arkansas (3)
Asia (21185)
Australia (2804)
California (3222)
Canada (1496)
China (551)
Colorado (143)
Connecticut (129)
Delaware (128)
Europe (43908)
Florida (607)
Georgia (65)
Hawaii (1)
Idaho (11)
Illinois (356)
India (44)
Indiana (240)
Iowa (2)
Japan (254)
Kansas (77)
Kentucky (20)
Louisiana (4)
Maine (2)
Maryland (426)
Massachusetts (2646)
Michigan (49)
Minnesota (165)
Mississippi (1)
Missouri (33)
Montana (8)
Nebraska (7)
Nevada (16)
New Hampshire (8)
New Jersey (1414)
New Mexico (7)
New York (910)
North Carolina (625)
North Dakota (2)
Northern California (1479)
Ohio (80)
Oklahoma (5)
Oregon (18)
Pennsylvania (756)
Puerto Rico (12)
Rhode Island (17)
South America (512)
South Carolina (10)
Southern California (1392)
Tennessee (53)
Texas (457)
United States (12880)
Utah (62)
Virginia (160)
Washington D.C. (42)
Washington State (224)
West Virginia (1)
Wisconsin (38)
Wyoming (1)
280,626 Results for "biofrontera pharmaceuticals gmbh".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Last Patient Completes Biofrontera’s Phase 1 Pharmacokinetics Study of Ameluz® for Treatment of Actinic Keratoses on the Trunk and Extremities
December 5, 2025
·
5 min read
Press Releases
Biofrontera Inc. Announces Data Base Locks for Two Clinical Studies Supporting Key Data and Regulatory Milestones
January 9, 2026
·
7 min read
Press Releases
Biofrontera Inc. Completes Transfer of Ameluz® and RhodoLED® FDA approval and Associated Intellectual Property Portfolio
December 19, 2025
·
4 min read
Press Releases
Biofrontera Inc. Reports Third Quarter 2025 Financial Results and Provides a Business Update
November 14, 2025
·
13 min read
Press Releases
Biofrontera Inc. Announces Record Preliminary Fourth Quarter 2025 Revenues between $17.0 Million and $17.5 Million, Representing Approximately 35% Year-Over-Year Growth
January 14, 2026
·
5 min read
Press Releases
Biofrontera Inc. Announces Filing of Supplemental New Drug Application (sNDA) for the Treatment of Superficial Basal Cell Carcinoma (sBCC) with Ameluz®-PDT
December 3, 2025
·
6 min read
Press Releases
Biofrontera Inc. announces sale of license to Xepi® Antibiotic Cream to Pelthos Therapeutics Inc. for up to $10M
November 10, 2025
·
4 min read
Press Releases
Biofrontera Inc. to Report Third Quarter 2025 Financial Results on November 12, 2025 and Host a Conference Call on November 13, 2025
November 6, 2025
·
1 min read
Press Releases
Biofrontera Inc. Announces Major Restructuring of Relationship With Biofrontera AG Backed By $11 Million Investment
July 1, 2025
·
5 min read
Press Releases
Biofrontera Inc. to Participate in the Lytham Partners Fall 2025 Investor Conference on September 30, 2025
September 29, 2025
·
1 min read
1 of 28,063
Next
